Finance

Beta
Lists
MGX:NASDAQ
Metagenomi Therapeutics Inc
USD 1,25
+5,04%
(+0,060) 1D
26 Jun., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MGX...
Open
USD 1,21
High
USD 1,30
Low
USD 1,21
Mkt. cap
47,06 m
Avg. vol.
168,94 k
Volume
208,64 k
52-wk high
USD 3,95
52-wk low
USD 1,13
EPS
-USD 2,30
Shares outstanding
37,65 m
No. of employees
118
Open
USD 1,21
High
USD 1,30
Low
USD 1,21
Mkt. cap
47,06 m
Avg. vol.
168,94 k
Volume
208,64 k
52-wk high
USD 3,95
52-wk low
USD 1,13
EPS
-USD 2,30
Shares outstanding
37,65 m
No. of employees
118
News stories
From sources across the web
About Metagenomi Therapeutics Inc
CEO-
Employees118
Founded2016
HeadquartersEmeryville, Kalifornië, Verenigde State van Amerika
Sector-
Websitemetagenomi.co
Analyst ratings
Based on 3 analysts giving stock ratings to MGX in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for MGX in the last 3 months.
Highest
Current USD 1,25
USD 9,00 (+620,00%)
Average
USD 8,00 (+540,00%)
Lowest
USD 7,00 (+460,00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geulah Livshits
Chardan Capital
Buy
Reiterated
USD 7,00
+460%
05/13/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
USD 9,00
+620%
05/11/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/11/2026
Last report
11 Mei 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-USD 0,61 / -USD 0,55
-10,91%miss
Revenue / Est. (USD)
1,25 m / 5,92 m
-78,94%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
8,51 m
8,66 m
3,91 m
1,25 m
Cost of goods sold
22,51 m
25,28 m
21,50 m
863,00 k
Cost of revenue
22,51 m
25,28 m
21,50 m
863,00 k
Research and development expenses
-
-
-
18,44 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,99 m
6,22 m
6,78 m
6,54 m
Operating expense
6,99 m
6,22 m
6,78 m
24,97 m
Total operating expenses
29,50 m
31,50 m
28,28 m
25,84 m
Operating income
-20,99 m
-22,84 m
-24,37 m
-24,59 m
Other non operating income
-70,00 k
-2,00 k
-11,00 k
-1,00 k
EBT including unusual items
-19,86 m
-20,63 m
-22,49 m
-23,05 m
EBT excluding unusual items
-18,57 m
-20,63 m
-22,49 m
-23,05 m
Income tax expense
44,00 k
-234,00 k
34,00 k
10,00 k
Effective tax rate
-0,22%
1,13%
-0,15%
-0,04%
Other operating expenses
-
-
-
-
Net income
-19,91 m
-20,39 m
-22,53 m
-23,06 m
Net profit margin
-233,85%
-235,51%
-576,02%
-1 847,68%
Earnings per share
-0,54
-0,55
-0,60
-0,61
Interest and investment income
2,48 m
2,21 m
1,88 m
1,54 m
Interest expense
-
-
-
-
Net interest expenses
2,48 m
2,21 m
1,88 m
1,54 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-19,65 m
-21,52 m
-23,07 m
-23,31 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of MGX
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer